ArticleOrphanet journal of rare diseases2025
Epidemiological characteristics and natural history of porphyria - a twenty-year population-based analysis in Taiwan.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPorphyrias are a group of rare, genetic disorders of heme biosynthesis in which reduced activity of any of the eight pathway enzymes leads to accumulation of intermediates and distinct clinical syndromes. These disorders are heterogeneous—not a single polymorphic condition—and are associated with impaired quality of life and increased mortality. Global epidemiological data, particularly from Asia, remain limited. This study analyzes population-based data from Taiwan to provide real-world evidence.
methodsThis study utilized the Taiwan National Health Insurance Research Database (~ 23 million population), which is linked with the Cause of Death Database and the Registry for National Health Insurance Catastrophic Illness Card database. Cases were validated through the rare disease registry of the Health Promotion Administration. The annual case numbers (2002–2022) were analyzed, with follow-up data on survival and causes of death. Outpatient and inpatient visits by specialty (2001–2022) and the average annual number of medical visits per person (2001–2022), including outpatient, inpatient and emergency visits, were assessed.
resultsAmong 126 patients with porphyria, 77.0% were female, with a mean age at diagnosis of 35.12 years. The annual incidence ranges from 0.04 to 0.62 per million, with a prevalence of 5.15 per million in 2022. The neurology, family medicine, and otolaryngology departments accounted for the most outpatient visits, whereas hospitalizations were common in the pediatrics, neurology, and gastroenterology departments. The mortality rate was 1543.4 per 100,000 people, and healthcare utilization was significantly 2-fold and above than that in the general population.
conclusionsThe incidence and prevalence of porphyria in Taiwan are lower than those reported in previous studies. The high mortality rate and diverse clinical manifestations emphasize the need for early diagnosis and timely management to reduce the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.